Versartis (United States)

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

Volker Schellenberger, Chia‐Wei Wang, Nathan C. Geething et al. · Nature Biotechnology · 2009 · 460 citations

Life Sciences, Biochemistry, Molecular Biology +4

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

Jeffrey L. Cleland, Nathan C. Geething, Jerome A. Moore et al. · Journal of Pharmaceutical Sciences · 2012 · 77 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose

Nathan C. Geething, Wayne To, Benjamin Spink et al. · PLoS ONE · 2010 · 59 citations · Full text

Pharmacy, Pharmaceutical Biotechnology, Pharmacokinetics +16

A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency

Wayne V. Moore, Huong Jil Nguyen, Gad B. Kletter et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 50 citations · Full text

Pharmacy, Endocrinology, Pediatrics +17

A Long-Acting Human Growth Hormone With Delayed Clearance (VRS-317): Results of a Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Growth Hormone–Deficient Adults

Kevin C.J. Yuen, Gerard S. Conway, Vera Popović et al. · The Journal of Clinical Endocrinology & Metabolism · 2013 · 49 citations · Full text

Pharmacy, Endocrinology, Pharmacokinetics +14